- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01497990
Pharmacokinetics Ertapenem Burns
November 2, 2012 updated by: Nantes University Hospital
Pharmacokinetics of Ertapenem When Used in Empiric Treatment in Burn Patients. Prospective Open Label Study.
This study will examine the pharmacokinetics of ertapenem in ventilated badly (> 30% SCT) burn patients.
Study Overview
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nantes, France, 44000
- Nantes University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients aged 18 to 70 years
- Burned on 30 to 60% of their body surface
- Mechanical ventilation
- Hospitalized in the intensive care unit of Nantes University Hospital for less than 8 days.
- Which the family gave consent
- insured
Exclusion Criteria:
- Patients whose family refused to sign the consent for participation.
- Patients allergic to beta lactam
- Patients with renal failure with creatinine clearance <80 ml.mn-1
- Pregnant women
- Persons protected by the law
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ertapenem
The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
|
The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of serum concentrations of total ertapenem from the second injection in order to calculate Cmax, Vz, ClP , ClR , ClNR , fe, T1/2b et AUC0 - alpha.
Time Frame: Blood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injection
|
Current study the pharmacokinetics (Cmax, Vz, ClP , ClR , ClNR , fe, T1/2beta, AUC 0 - alpha) in a population of burn patients.
|
Blood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time between injection and observation of a serum concentration less than the critical concentration below
Time Frame: Blood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injection
|
Check that the injection of 1 g ertapenem achieves a serum concentration above the critical concentration of bacteria usually isolated in cases of early infection for more than 40% of the time between two injections (t / MIC> 40 %), this ratio being one of the criteria predictive of efficacy of beta-lactam antibiotics.
|
Blood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injection
|
Time needed between injections in order to obtain a concentration greater than the critical concentration below for the duration of time between two injections
Time Frame: Blood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injection
|
Study when two injections of ertapenem serum concentrations fall below the critical concentrations of bacteria usually isolated in cases of early infection, if they become.
|
Blood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Ronan LE FLOCH, PH, Nantes University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
December 15, 2011
First Submitted That Met QC Criteria
December 22, 2011
First Posted (Estimate)
December 23, 2011
Study Record Updates
Last Update Posted (Estimate)
November 4, 2012
Last Update Submitted That Met QC Criteria
November 2, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09/3-W
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burn Patients
-
Wake Forest UniversityWashington University School of Medicine; United States Department of Defense; University of North Carolina, Chapel HillTerminatedCritically Injured Burn PatientsUnited States
-
RWTH Aachen UniversityCompletedBurn Patients
-
Bispebjerg HospitalUnknownBurn Scar PatientsDenmark
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Société des Produits Nestlé (SPN)CompletedEffect of Early Enteral Tube Feeding Nutrition With an Immune Enhancing Diet in Severe Burn PatientsInfections on | Severe Burn PatientsFrance
-
Isra UniversityCompleted
-
Hospices Civils de LyonCompletedPatients With Massive Burn InjuryFrance
-
Shin Kong Wu Ho-Su Memorial HospitalCompletedPatients With Major Burn Injury in Formosa FunCost ExplosionTaiwan
-
Xequel Bio, Inc.United States Department of DefenseWithdrawnThermal Burn | Second Degree Burn
-
Indonesia UniversityRecruitingBurn Degree Second | Burn Degree ThirdIndonesia
Clinical Trials on Ertapenem
-
University Medical Center GroningenCompleted
-
University of MichiganCompletedAcute Kidney FailureUnited States
-
Catholic University of the Sacred HeartMerck Sharp & Dohme LLCUnknown
-
Merck Sharp & Dohme LLCCompleted
-
Hartford HospitalMerck Sharp & Dohme LLCCompletedHealthyUnited States
-
Klinikum Hanover-Siloah HospitalUnknownAcute Disease | Diverticulitis, ColonicGermany
-
Prince of Songkla UniversityUnknownPatients With Urosepis and Received Ertapenem for TreatmentThailand
-
Merck Sharp & Dohme LLCCompleted
-
Albany College of Pharmacy and Health SciencesMerck Sharp & Dohme LLCCompletedEnd Stage Renal Disease | Continuous Ambulatory Peritoneal DialysisUnited States